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Abstract
Objective:  To  investigate  the  association  between  serum  uric  acid  concentration  according  to
the  presence  or  absence  of  non-alcoholic  fatty  liver  disease  (NAFLD)  and/or  metabolic  syndrome
(MS)  in  overweight  or  obese  children  and  adolescents.
Methods:  This  was  a  cross-sectional  study  conducted  from  April  of  2009  to  March  of  2010,
including 129  children  and  adolescents  treated  at  the  Center  for  Childhood  Obesity.  Anthro-
pometric  data,  blood  pressure  measurements,  and  laboratory  test  results  were  obtained,  and
NAFLD  diagnosis  was  made  by  ultrasound.  The  diagnosis  of  MS  was  made  using  the  criteria  of
the  National  Cholesterol  Education  Program/Adult  Treatment  Panel  III,  adapted  to  age  range.
The  chi-squared  test  or  or  Fisher’s  test  were  used  to  evaluate  the  association  of  uric  acid  with
the  groups,  with  a  95%  conﬁdence  interval.  One-way  analysis  of  variance  (ANOVA)  was  used  for
comparison  of  means.  Multiple  logistic  regression  was  used  for  adjustment  of  variables.  The
data  were  analyzed  with  the  Statistical  Package  for  Social  Sciences  (SPSS),  release  17.
Results: High  levels  of  uric  acid  were  signiﬁcantly  associated  with  adolescence,  MS,  and  sys-
tolic  blood  pressure.  The  highest  quartile  of  uric  acid  showed  signiﬁcantly  higher  values  of  body
mass  index,  waist  circumference,  systolic  blood  pressure,  diastolic  blood  pressure,  triglyceri-
des,  total  cholesterol,  and  homeostatic  model  assessment  index  (HOMA-IR),  and  lower  mean
values  of  HDL  cholesterol.  In  the  ﬁnal  model,  only  age  range  and  the  presence  of  MS  remained
associated  with  uric  acid  levels.
Conclusions:  High  levels  of  uric  acid  were  associated  with  MS  and  adolescence,  which  was  not
observed with  NAFLD.
© 2013  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Relac¸ão  entre  ácido  úrico  e  os  componentes  da  síndrome  metabólica  e  esteatose
hepática  não  alcoólica  em  crianc¸as  e  adolescentes  com  sobrepeso  ou  obesidade
Resumo
Objetivo:  Veriﬁcar  a  relac¸ão  entre  a  concentrac¸ão  de  ácido  úrico  sérico  de  acordo  com  a
presenc¸a ou  não  de  esteatose  hepática  não  alcoólica  e/ou  síndrome  metabólica  (SM)  em  crianc¸as
e adolescentes  com  sobrepeso  ou  obesidade.
Métodos:  Estudo  transversal  desenvolvido  no  período  de  abril/2009  a  marc¸o/2010,  incluindo
129 crianc¸as  e  adolescentes  atendidos  no  Centro  de  Obesidade  Infantil.  Foi  realizada
antropometria, aferic¸ão  da  pressão  arterial,  dosagem  dos  exames  laboratoriais  e  o  diagnóstico
de  esteatose  hepática  por  exame  ultrassonográﬁco.  Para  o  diagnóstico  de  SM,  foram  utilizados
os  critérios  da  National  Cholesterol  Education  Program/Adult  Treatment  Panel  III  adaptados
para  faixa  etária.  Para  avaliac¸ão  da  associac¸ão  do  ácido  úrico  com  os  grupos,  foi  realizado  o
teste  do  Qui-quadrado  ou  Fisher,  adotando-se  o  intervalo  de  conﬁanc¸a de  95%.  Para  comparac¸ão
de médias,  utilizou-se  o  ANOVA  One  Way.  Para  o  ajuste  das  variáveis  foi  utilizada  a  regressão
logística múltipla.  Os  dados  foram  processados  no  SPSS  versão  17.
Resultados: Níveis  elevados  de  ácido  úrico  associaram-se  signiﬁcativamente  à  adolescência,
SM e  pressão  arterial  sistólica.  O  maior  quartil  de  ácido  úrico  apresentou  valores  médios  signi-
ﬁcativamente  mais  elevados  de  índice  de  massa  corpórea,  circunferência  abdominal,  pressão
arterial  sistólica,  pressão  arterial  diastólica,  triglicerídeos,  colesterol  total  e  HOMA-IR,  e  menor
média  do  colesterol  HDL.  No  modelo  ﬁnal  só  permaneceram  associadas  aos  níveis  de  ácido  úrico
a  faixa  etária  e  a  presenc¸a de  síndrome  metabólica.
Conclusões:  Níveis  elevados  de  ácido  úrico  estiveram  associados  à  síndrome  metabólica  e  à
adolescência,  o  que  não  foi  observado  com  a  esteatose  hepática.
© 2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Uric  acid  at  normal  plasma  levels  has  been  known  to
exert a  neuroprotective  effect,  by  acting  as  a  free-radical
scavenger; however,  several  observational  studies  have  indi-
cated  that  high  levels  of  serum  uric  acid  are  associated
with the  risk  of  cardiovascular  disease  and  may  be  useful
in the  assessment  of  individual  cardiovascular  risk.  Further-
more, high  uric  acid  levels  have  also  been  associated  with
insulin resistance  (IR),  diabetes  mellitus  type  2  (DM2),  and
metabolic syndrome  (MS).1,2
Among  these  cardiometabolic  alterations,  MS  has  been
stressed, as  it  represents  a  set  of  risk  factors,  which  con-
sists of  alterations  in  the  metabolism  of  carbohydrates
-- hyperinsulinemia,  IR,  glucose  intolerance  or  DM2,  lipid
metabolism alterations  (increased  triglycerides  (TG)  and/or
decreased cholesterol  bound  to  high-density  lipoprotein
[HDL]), abdominal  obesity,  and  high  blood  pressure.3
The  hepatic  expression  of  MS  is  nonalcoholic  fatty  liver
disease (NAFLD),  which  is  characterized  by  fat  deposition
in the  hepatocytes  of  patients  with  little  or  no  alcohol
ingestion.4 In  a  study  of  102  adults  diagnosed  with  dia-
betes, it  was  observed  that  almost  half  NAFLD,  and  they  also
presented higher  BMI  and  uric  acid  levels  than  individuals
without NAFLD.5
Despite  evidence  that  uric  acid  is  considered  a  car-
diometabolic risk  factor,6 there  is  no  reference  in  the
literature to  the  association  between  this  biochemical  vari-
able and  steatosis  in  the  pediatric  population,  especially
among obese  or  overweight  children  and  adolescents.  Thus,
this study  aimed  to  investigate  the  association  between
t
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cerum  uric  acid  levels  according  to  the  presence  or  absence
f NAFLD  and/or  MS  in  overweight  or  obese  children  and
dolescents.
ethods
his  was  a  cross-sectional  study  with  a quantitative
pproach performed  between  July  of  2009  and  March  of
010, as  part  of  a  larger  project  entitled  ‘‘Prevalence  of
ardiometabolic risk  factors  in  overweight  or  obese  children
nd adolescents’’,  approved  by  the  Ethics  Research  Commit-
ee of  the  Universidade  Estadual  da  Paraíba,  under  process
o. 0040.0.133.000-08.
A convenience  sample  was  used,  consisting  of  overweight
r obese  children  and  adolescents  aged  between  2  and  18
ears who  were  referred  by  health  teams  to  the  Childhood
besity Center  (Centro  de  Obesidade  Infantil  --  COI),  imple-
ented at  the  Instituto  de  Saúde  Elpídio  de  Almeida  (ISEA),
ocated in  Campina  Grande,  state  of  Paraíba,  Brazil,  The
nrollment was  carried  out  at  the  Basic  Health  Units  under
he supervision  of  the  health  department  of  that  municipal-
ty. The  COI  consists  of  researchers  and  a  multidisciplinary
eam comprising  endocrinologists,  nutritionists,  psychol-
gists, nurses,  pharmacists,  social  workers,  and  physical
rainers.
A total  of  131  patients  were  evaluated  during  this  period;
hose who,  at  the  time  of  data  collection,  had  any  chronic
isease such  as  secondary  hypertension,  diabetes  mellitus
ype 1,  diagnosis  of  liver  disease  or  inﬂammatory  pro-
ess, alcoholism,  smoking,  or  who  were  using  medication
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hat  interfered  with  glucose  metabolism  or  lipids,  such  as
teroids, were  excluded.  Two  individuals  were  excluded  due
o corticosteroid  use;  thus,  a  total  of  129  individuals  were
valuated.
Parents or  guardians  who  agreed  to  let  their  children
articipate in  the  study  signed  an  informed  consent,  after
eing informed  of  the  goals,  methods,  and  procedures  to  be
ollowed.
Data on  socioeconomic  status  and  personal  and  fam-
ly history  were  obtained;  anthropometric  measurements
ere assessed  by  previously  trained  students,  and  labora-
ory testing  and  ultrasound  examination  were  scheduled.
wo measurements  of  anthropometric  data  (weight,  height,
nd waist  circumference)  were  performed  on  the  same  day,
nd the  mean  value  was  used  in  the  analysis.  Nutritional  sta-
us was  classiﬁed  using  the  World  Health  Organization  (WHO)
nthro (for  children  younger  than  5  years)  and  AnthroPlus
≥ 5  years)  software,  obtaining  the  z-score  related  to  body
ass index  (BMI)  for  age.
For  children  younger  than  5  years,  the  use  of  the
nternational reference  by  the  WHO  published  in  2006  is
ecommended, classifying  them  as:  at  risk  for  overweight
z score  +  1  <  BMI  ≤  z  score  +  2),  overweight  (z  score  +  2  <  BMI
 z  score  +  3),  and  obesity  (BMI  >  z  score  +  3).  For  children
ged 5  to  19  years,  the  use  of  the  reference  published  by
he WHO  in  2007  is  recommended,  considering  the  follow-
ng categories:  overweight  (z  score  +  1  <  BMI  ≤  z  score  +  2),
besity (z  score  +  2  <  BMI  ≤  z  score  +  3),  and  severe  obesity
BMI >  z  score  +  3).7
For  statistical  analysis,  the  nutritional  status  was  cate-
orized into  two  groups,  considering  children  younger  than
 years  to  be  overweight  when  z  score  +  1  <  BMI  ≤  z  score  +  3
nd obese,  when  BMI  >  z  score  +  3;  those  aged  5  years  or  older
ere considered  to  be  overweight  when  z  score  +  1  <  BMI  <  z
core +  2  and  obese,  when  BMI  ≥  z  score  +  2.
The waist  circumference  (WC)  was  measured  using  an
nelastic tape  at  midpoint  between  the  superior  border  of
he iliac  crest  and  the  inferior  costal  margin.  Values  >90th
ercentile  were  considered  increased.  However,  girls  with
C ≥  88  cm  and  boys  with  WC  ≥  102  cm  were  considered  as
aving altered  results  regardless  of  the  percentile.8
Three  blood  pressure  measurements  were  performed
ith a  two-minute  interval  between  them,  according  to
he method  established  in  the  V  Brazilian  guidelines  on
ypertension.9 The  mean  of  the  last  two  measurements  was
onsidered as  the  systolic  (SBP)  and  diastolic  (DBP)  blood
ressure values.
The  diagnosis  of  steatosis  was  based  on  the  results  of
ltrasonography of  the  upper  abdomen,  performed  at  the
ospital Universitário  Alcides  Carneiro  (HUAC),  by  a  sin-
le radiologist  blinded  to  clinical  data  and  laboratory  test
esults. The  equipment  used  was  a  MedisonSonoAce  Prime
000EX, with  a  multifrequency  convex  transducer  of  5  MHz.
lterations in  liver  parenchyma  were  classiﬁed  as  nor-
al, mild,  moderate,  and  severe  diffuse  steatosis.10 This
lassiﬁcation uses  as  parameters  the  liver  echogenicity  in
omparison with  the  renal  cortex,  the  echo  penetration
ntensity in  the  liver  parenchyma,  the  diaphragm  visibility,
nd the  echogenicity  of  the  liver  vascular  structures.11
Blood  collection  was  performed  after  a  10  to  12  hour
ast, at  the  Clinical  Analysis  Laboratory  of  the  Universidade
stadual da  Paraíba  (LAC/UEPB).
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The  measurements  of  uric  acid,  HDL-C,  TG,  and  glucose
ere performed  by  the  enzymatic  colorimetric  method  in
utomated equipment  (BioSystems  310  model),  according
o the  recommendations  of  the  Labtest®  kit  manufacturer.
nsulin was  measured  by  chemiluminescence  in  automated
quipment (IMMULITE  1000  -  SIEMENS®).  Hyperuricemia
as considered  with  values  >  5.5  mg/dL.12 The  homeostatic
odel assessment  index  (HOMA-IR)  was  used  as  the  criterion
or the  diagnosis  of  IR.  The  cutoff  used  was  HOMA-IR  ≥  2.5.13
The  diagnosis  of  MS  was  attained  using  the  criteria
ecommended by  the  National  Cholesterol  Education  Pro-
ram/Adult Treatment  Panel  III14 adapted  to  the  age  group,
hich considers  as  MS  the  presence  of  at  least  three  of  the
ollowing items:  WC  ≥  90th percentile  for  age,  gender,  and
thnicity; TG  ≥  130  mg/dL  and/or  HDL-C  <  45  mg/dL,  fasting
lucose ≥  100  mg/dL,  SBP  and/or  DBP  >  90th percentile  for
ender, height,  and  age.  The  cutoffs  for  TG,  HDL-C,  and
asting glucose  followed  the  values  recommended  in  the  I
uideline  for  atherosclerosis  prevention  in  childhood  and
dolescence.15
The  following  groups  were  considered  according  to  the
resence and/or  absence  of  MS  and  NAFLD:  G1  -  presence
f MS  and  steatosis;  G2  -  presence  of  MS  without  steatosis;
3 -  absence  of  MS  and  presence  of  steatosis;  G4  --  absence
f MS  and  steatosis.
The  data  were  presented  as  proportions,  means,  and
tandard deviations  (SD).  After  applying  the  Kolmogorov-
mirnoff test  to  assess  for  normality,  the  association  of
ric acid  levels  with  gender,  age  range,  ethnicity,  nutri-
ional status,  WC,  SBP,  DBP,  TG,  fasting  glucose,  IR,  MS,
nd hepatic  steatosis  was  veriﬁed  using  the  chi-squared
r Fisher’s  exact  test,  when  necessary,  with  a  95%  conﬁ-
ence interval  (95%  CI)  and  prevalence  ratio  (PR).  One
ay analysis  of  variance  (ANOVA)  was  used  for  comparison
f the  means  of  MS  components  according  to  quartiles  of
ric acid  and,  when  necessary,  using  Bonferroni’s  post  hoc
est.
Multiple logistic  regression  was  used  for  variable  adjust-
ent, whose  criterion  for  variable  inclusion  was  the
ssociation with  the  dependent  variable  in  the  bivariate
nalysis with  p-value  <  0.20.  The  variables  were  included  in
he regression  analysis  using  the  ‘enter’  method,  according
o the  decreasing  value  of  odds  ratio.  The  Hosmer-Lemeshow
est was  used  as  a  measure  of  quality-of-ﬁt  for  the  logistic
egression models,  in  which  a  p-value  ≥  0.05  indicates  that
he model  is  adjusted.
All analyses  were  two-tailed  and  were  performed  using
he Statistical  Package  for  Social  Sciences  (SPSS),  release
7.0 (SPSS  Inc,  Chicago,  USA)  with  the  signiﬁcance  level  set
t 5%.
esults
f  the  129  children  and  adolescents  evaluated,  62.8%
81/129) were  females  and  65.9%  (85/129)  were  non-white.
he mean  age  was  11.27  (SD  =  ±3.72)  and  age  distribution
ndicated that  61.4%  (86/129)  were  adolescents  (10  to  18
ears). Regarding  the  socioeconomic  characteristics,  56.6%
69/122) had  a family  income  of  up  to  two  Brazilian  minimum
ages. With  regard  to  maternal  education,  57.5%  (73/127)
ad completed  high  school.
oUric  acid:  association  with  hepatic  steatosis  and  MS  
The  mean  uric  acid  level  found  was  4.191  mg/dL  (±
SD =  2.32).  Hyperuricemia  was  observed  in  12.4%  (16/129)
of assessed  individuals,  MS  in  49.6%  (64/129),  and  RI  was
diagnosed in  44.2%  (57/129)  of  them.  NAFLD  was  diagnosed
in 28.7%  (37/129)  of  children  and  adolescents.
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Table  1  Social,  anthropometric,  clinical  and  laboratory  variable
obese  children  and  adolescents.  Centro  de  Obesidade  Infantil,  ISEA
Variables  Uric  acid  
>5.5  mg/dL  (n  =  16)  n  (%) ≤  5.5  m
Gender  
Male  8  (16.7)  40  (83
Female 8  (9.9)  73  (90
Age range  
Adolescence  15  (17.4)  71  (82
Childhood 1  (2.3)  42  (97
Ethnicity 
White  8  (18.2) 36 (81
Non-white 8  (9.4)  77  (90
Nutritional status  
Overweight  15(14.0)  92  (86
Obesity 1  (4.5)  21  (95
WC 
Increased  15  (14.4)  89  (85
Normal 1  (4.0)  24  (96
SBP 
SBP  ≥  P90  10  (22.7)  34  (77
SBP <  P90  6  (7.1)  79  (92
DBP 
DBP  ≥  P90  12  (14.5)  71  (85
DBP <  P90  4  (8.7)  42  (91
TG 
Altered  10  (19.6) 41 (80
Normal 6  (7.7)  72  (92
HDL-c 
Altered  15  (13.6)  95  (86
Normal 1  (5.3)  18  (94
Glycemia 
Altered  0  (0.0)  1  (10
Normal 16  (12.5)  112  (87
IR 
Present  10  (17.5)  47  (82
Absent 6  (8.3)  66  (91
MS 
Present  12  (18.8)  52  (81
Absent 4  (6.2)  61  (93
Steatosis 
Present  6  (16.2)  31  (83
Absent 10  (10.9)  82  (89
CI, conﬁdence interval; DBP, diastolic blood pressure; HDL-C, high-den
PR, prevalence ratio; SBP, systolic blood pressure; TG, triglycerides; W
a Fisher’s p.415
Low levels  of  HDL-C  were  observed  in  85.3%  (110/129)
f the  assessed  individuals,  and  39.5%  (51/129)  had  hyper-
riglyceridemia. Hyperglycemia  was  observed  in  only  0.8%
1/129) of  the  assessed  individuals.  SBP  was  high  in  34.1%
44/129) and  DBP  in  64.3%  (83/129)  of  the  individuals.
s  according  to  serum  levels  of  uric  acid  in  129  overweight  or
,  Campina  Grande-PB,  2009-2010.
PR  (95%  CI)
g/dL  (n  =  113)  n  (%) p
1.82  (0.63  --  5.23)  0.258
.3)
.1)
8.87  (1.13  --  69.61)  0.020
.6)
.7)
2.13  (0.74  --  6.15)  0.152
.8)
.6)
3.42  (0.42  --  27.37)  0.314
.0)
.5)
4.04  (0.50  --  32.17)  0.307
.6)
.0)
3.87  (1.30  -11.50)  0.010
.3)
.9)
1.77  (0.53  --  5.85)  0.413
.5)
.3)
2.92  (0.99  --  8.63)  0.083
.4)
.3)
2.84  (0.35  --  22.88)  0.464
.4)
.7)
-  -
0.0)
.5)
2.34  (0.79  --  6.88)  0.115
.5)
.7)
3.51  (1.07  --  11.57)  0.035a
.3)
.8)
1.58  (0.53  --  4.73)  0.405
.8)
.1)
sity lipoprotein; IR, insulin resistance; MS, metabolic syndrome;
C, waist circumference.
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Table  2  Mean  values  of  BMI,  blood  glucose,  WC,  SBP,  DBP  and  HOMA-IR  quartiles  according  to  uric  acid  of  129  overweight  or
obese  children  and  adolescents.  Centro  de  Obesidade  Infantil,  ISEA,  Campina  Grande-PB,  2009-2010.
Uric  acid
Variables  P1  <  3.0  n  =  30  P25  3.0-3.9  n  =  32  P50  4.0-4.8  n  =  32  P75  ≥  4.9  n  =  35  p
Mean (SD)  Mean  (SD)  Mean  (SD)  Mean  (SD)
BMI  25.02  (2.74)  26.66  (4.25)  28.17  (4.55)  30.33  (4.32)  0.000a
WC  80.15  (8.88)  81.77  (12.25)  89.54  (12.38)  93.12  (12.52)  0.000b
SBP  103.20  (10.51)  104.84  (10.19)  110.53  (11.34)  113.86  (12.66)  0.001c
DBP  69.20  (8.70)  68.91  (7.15)  75.31  (9.66)  75.69  (11.86)  0.003d
TG  106.00  (53.87)  117.59  (54.94)  134.63  (68.09)  165.40  (77.28)  0.002e
HDL-c  38.50  (11.59)  39.13  (7.54)  38.53  (7.56)  33.23  (6.49)  0.014f
HOMA-  IR 1.81  (1.09)  2.18  (1.62)  2.52  (1.48)  3.39  (1.76)  0.000g
Glycemia  78.90  (7.75) 80.56  (7.67) 79.75 (6.75) 82.69 (6.54)  0.172
BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein; HOMA-IR, homeostatic model assessment index;
SBP, systolic blood pressure; SD, standard deviation; TG, triglycerides; WC, waist circumference.
a Differences between quartile 1 with 3 and 4, and between 2 with 4.
b Between quartile 1 with 3 and 4, and between 2 with 3 and 4.
c Difference between quartile 1 and 4, and 2 and 4.
d Between quartile 1 and 4, and 2 and 4.
e Difference between quartile 1 and 4 and 2 and 4.
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g Difference between quartile 1 and 4.
Table  1  shows  that  higher  values  of  uric  acid  were
igniﬁcantly associated  with  adolescence,  altered  SBP,
ypertriglyceridemia, and  MS.  No  signiﬁcance  was  observed
hen correlating  levels  of  uric  acid  with  the  presence  of
teatosis. The  chance  of  having  hyperuricemia  was  higher
n the  following  groups:  adolescence  (PR  =  8.87),  high  SBP
PR =  3.87),  and  those  with  MS  (PR  =  3.51).
The  quartiles  of  uric  acid  observed  were:  <  3.0;  3.0-3.9;
.0-4.8; and  ≥  4.9.  Table  2  shows  that  the  group  consist-
th thng of  individuals  from  the  4 quartile  (percentile  >  75 for
ric acid  values)  showed  signiﬁcantly  higher  values  of  BMI,
C, SBP,  DBP,  TG,  and  HOMA-IR,  and  lower  mean  of  HDL-C
Table 2).
w
g
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Table  3  Uric  acid  values  according  to  the  presence  and/or  absenc
or  obese  children  and  adolescents.  Centro  de  Obesidade  Infantil,  I
Uric  a
Variables  
Presence  of  MS  and  steatosis  
Presence  of  MS  and  absence  of  steatosis  
Absence  of  MS  and  presence  of  steatosis  
Absence  of  MS  and  steatosis  
CI, conﬁdence interval; MS, metabolic syndrome; SD, standard deviatio
p = 0.220.
Table  4  Crude  and  adjusted  odds  ratio  (95%  conﬁdence  interval)  
and  adolescents.  Centro  de  Obesidade  Infantil,  ISEA,  Campina  Gra
Parameter  Variables  Crude
OR
Uric  acid  Age  range  (adolescents:  10  to  18  years)  8.87  
Presence  of  metabolic  syndrome  3.51  There  was  no  association  between  levels  of  uric  acid  and
he combined  groups  according  to  the  presence/absence  of
S and  nonalcoholic  hepatic  steatosis  (Table  3).
Through  multiple  logistic  regression  analysis,  it  was
bserved that  in  the  ﬁnal  model,  only  age  and  the
resence of  MS  remained  associated  with  uric  acid  lev-
ls. It  was  observed  that,  among  adolescents,  the  odds
f having  increased  uric  acid  levels  was  approximately
ine times  higher  than  among  children;  when  compared
ith patients  with  MS,  this  probability  was  3.7  times
reater. As  demonstrated  by  the  results  of  the  Hos-
er and  Lemeshow  test,  the  model  showed  a  good  ﬁt
Table 4).
e  of  metabolic  syndrome  and  liver  steatosis  in  129  overweight
SEA,  Campina  Grande-PB,  2009  -  2010.
cid
Mean  (mg/dL)  ±  SD  95%CI
4.5  ±  1.64  3.64-5.40
4.4  ±  1.79  3.87-4.91
4.7  ±  4.62  2.58-6.80
3.6  ±  1.05  3.29-3.92
n.
of  alterations  in  uric  acid  in  129  overweight  or  obese  children
nde-PB,  2009  --  2010.
Adjusted
OR
Adjusted
p-value  (95%CI)
p-value  Hosmer
and Lemeshow
9.24  0.035  (1.16-73.44)  0.853
3.67  0.036  (1.09-12.37)
ﬁ
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RUric  acid:  association  with  hepatic  steatosis  and  MS  
Discussion
Serum  uric  acid  is  the  primary  end  product  of  purine
metabolism in  humans,  and  its  levels  are  strictly  controlled
by the  balance  between  production  and  excretion.16 In  this
study, high  levels  of  uric  acid  were  associated  with  adoles-
cence and  MS.  It  is  noteworthy  that  there  was  no  association
between increased  levels  of  uric  acid  with  the  diagnosis  of
overweight and  obesity  and  with  the  presence  of  NAFLD.
In  this  study,  the  prevalence  of  MS  was  higher  than  that
found by  other  authors  who  evaluated  obese  children  and
adolescents,17,18 and  conﬁrms  previous  results  from  a  sample
of hypertensive  adults  from  Cuiabá,  state  of  Mato  Grosso,  in
which the  prevalence  of  high  levels  of  uric  acid  was  signiﬁ-
cantly higher  in  patients  with  MS.19
The  evidence  that  explains  the  association  of  uric  acid
with MS  is  based  on  two  mechanisms.  The  ﬁrst  mechanism
is related  to  the  fact  that  glucose  uptake  in  skeletal  mus-
cle partially  depends  on  the  increase  in  insulin-mediated
blood ﬂow,  stimulating  the  release  of  nitric  oxide  from
endothelial cells.  Components  of  MS  developed  in  mice  with
endothelial nitric  oxide  synthesis.  The  second  mechanism
is related  to  the  fact  that  uric  acid  induces  oxidative  and
inﬂammatory alterations  in  adipocytes,  since  xanthine  oxi-
doreductase (the  enzyme  that  generates  uric  acid  from
xanthine) is  expressed  in  adipocytes  and  is  critical  to  the
adipogenesis process.20
Paciﬁco  et  al.,21 in  a  study  performed  in  Italy  to  verify
the association  of  hyperuricemia  with  MS  and  atherosclerosis
in obese  children  and  adolescents,  concluded  that  patients
with high  uric  acid  levels  had  a  higher  incidence  of  carotid
atherosclerosis as  demonstrated  by  the  thickening  of  the
carotid intima-media,  assessed  by  Doppler  ultrasonography
of this  region.
It was  observed  that  individuals  with  high  SBP  were
approximately four  times  more  likely  to  have  hyperuricemia;
a biological  explanation  for  this  fact  is  supported  by  a  study
performed in  an  animal  model  with  rats,  which  demon-
strated that  after  induction  of  hyperuricemia  there  was
development of  hypertension,  probably  due  to  reduction  in
nitric oxide  in  renal  macula  densa  and  by  direct  stimulation
of the  renin-angiotensin  system,  as  both  mechanisms  cause
vasoconstriction and  therefore  increase  blood  pressure.22
Regarding  the  variables  of  lipid  metabolism  an  asso-
ciation between  uric  acid  levels  and  the  means  of  TG
and HDL  (inversely  associated  with  the  latter)  has  been
demonstrated,1,23 conﬁrming  the  ﬁndings  of  the  present
study.
The ﬁnding  of  hyperglycemia  in  this  age  group  is  unusual,
as the  more  frequent  manifestation  of  glucose  metabolism
is IR,  which  is  a  compensatory  mechanism,  while  glucose
tolerance remains  normal.24
Although  no  association  with  hepatic  steatosis  was
observed in  this  sample,  recent  studies  have  described  a
signiﬁcant association  between  high  levels  of  uric  acid  and
NAFLD, representing  an  independent  risk  factor  for  liver
disease.25--27
The  most  plausible  explanation  for  this  association,  which
has been  inferred  from  the  current  understanding  of  NAFLD
progression, would  be  the  ‘‘two-hit’’  theory.  According  to
this theory,  the  accumulation  of  fat  in  the  liver  is  the417
rst  ‘‘hit’’,  which  makes  the  hepatocytes  more  vulnera-
le to  further  damage  due  to  certain  triggers,  such  as  IR,
xcess inﬂammation,  alcohol  consumption,  and  obesity.  In
his process,  IR  plays  a  central  role  in  the  vicious  circle,
hich promotes  lipolysis  of  the  peripheral  adipose  tissue  and
ncreases the  inﬂux  of  free  fatty  acids  into  the  liver.  This  IR
eads to  hyperinsulinemia,  which  increases  the  synthesis  of
ric acid  and  decreases  its  renal  excretion.24
Oxidative  stress  appears  to  be  involved  in  the  ‘‘hit’’
rocess, which  promotes  lipid  peroxidation  and  the  inﬂam-
atory response.  Uric  acid  reﬂects  the  rate  of  cell  renewal,
hich in  itself  can  be  a  part  of  the  inﬂammatory  process,
aking it  a  pro-inﬂammatory  factor.  Uric  acid  increases
nterleukin (IL)-6  and  tumor  necrosis  factor  alpha  (TNF-
) levels.  Thus,  high  levels  of  uric  acid  in  blood  are  due
o oxidative  stress  that  occurs  in  response  to  metabolic
isorders.28
A  study  by  Roberts  et  al.29 demonstrated  that  uric  acid
learance in  the  obese  group  was  lower  than  in  the  control
roup, suggesting  that  hyperuricemia  in  the  obese  popu-
ation would  be  mainly  attributed  to  a  decrease  in  the
learance of  uric  acid,  rather  than  to  an  overproduction  of
rates.
The method  used  to  diagnose  NAFLD  was  considered  a
imitation of  the  present  study,  as  the  gold  standard  is
iopsy, an  invasive  and  expensive  technique.  Thus,  the  ultra-
ound technique  was  chosen,  which  has  been  widely  used  in
ublic health  studies  due  to  its  easy  accessibility,  safety,  and
xcellent sensitivity,  especially  when  evaluating  the  pedi-
tric population.
In conclusion,  high  levels  of  uric  acid  were  associated
ith MS  and  adolescence,  which  was  not  observed  with
AFLD. The  possibility  of  cardiovascular  complications  does
ot depend  on  a  particular  factor,  rather  on  the  concomitant
resence of  individual  characteristics  capable  of  increas-
ng this  possibility  --  symptomatic  or  not  --  in  target  organs
nd associated  clinical  complications.  Thus,  the  inclusion
f measurement  of  uric  acid  levels  in  the  assessment  pro-
ocols for  obese  or  overweight  children  and  adolescents  is
uggested, in  order  to  verify  possible  complications  of  early
ardiovascular alterations.
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